(trospium chloride + xanomeline tartrate)

all catalysts(0)

nothing on the calendar yet

News(10)

• BMS welcomes new multiple myeloma drug as generics batter current portfolio
  The FDA approves Zenbexus just as copycat competitors depress sales of Bristol Myers Squibb’s multiple myeloma drugs Pomalyst and Revlimid, which crashed 71% and 49% year-on-year, respectively, in…
  biospace · 6d ago
• MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
  Despite mixed results for its experimental schizophrenia treatment last month, MapLight Therapeutics is going all-in on the asset—at the expense of its preclinical programs.
  fiercebiotech · 7d ago
• As BMS’ Cobenfy struggles to gain traction, MapLight knocks on the door
  Despite the recent emergence of a new drug class, schizophrenia remains one of the most challenging neuropsychiatric diseases to treat—and Cobenfy's first steps into the market indicate there is st…
  biospace · 11d ago
• As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
  While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…
  biospace · 16d ago
• An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
  In fact, the former lost tens of billions of dollars in market value following reports of a potential tie-up between the pharmaceutical giants.
  biopharma_dive · 17d ago
• Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs
  Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
  biopharma_dive · 20d ago
• BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays
  Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milve…
  biospace · 21d ago
• Bristol Myers delays Cobenfy Alzheimer’s psychosis readout again amid another quarterly beat
  Investors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.
  fiercebiotech · 22d ago
• MapLight CEO on what investors missed in the biotech’s schizophrenia data
  Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."
  biopharma_dive · 22d ago
• MapLight dives despite positive data for schizophrenia drug
  Shares fell more than 66% Monday morning, which analysts suspect is due to investors seeing the data as not competitive with Bristol Myers' Cobenfy.
  biopharma_dive · 24d ago